Breaking Finance News

Puma Biotechnology Inc (NYSE:PBYI) target price raised to $89.00, released a report earlier today by Zacks Investment Research

Indicating a possible upside of 0.10%, Zacks Investment Research increased the stock price target of Puma Biotechnology Inc (NYSE:PBYI) to $89.00

Just yesterday Puma Biotechnology Inc (NYSE:PBYI) traded 0.26% higher at $81.10. The company’s 50-day moving average is $105.42 and its 200-day moving average is $75.89. The last stock close price is up 63.90% from the 200-day moving average, compared to the S&P 500 which has increased 0.03% over the same time. 212,578 shares of the stock were exchanged, down from an average trading volume of 897,720

See Chart Below

Puma Biotechnology Inc (NYSE:PBYI)

Puma Biotechnology Inc has a 52 week low of $28.35 and a 52 week high of $127.02 The company’s total market value is presently $0.

A total of 6 equity analysts have released a ratings update on PBYI. Two equity analysts rating the company a strong buy, four equity analysts rating the company a buy, two equity analysts rating the company a hold, zero brokerages rating the company a underperform, and finally zero brokerages rating the company a sell with a 12-month price target of $95.50.

General Company Details For Puma Biotechnology Inc (NYSE:PBYI)

Puma Biotechnology, Inc. is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of cancer. The Company focuses on in-licensing the development and commercialization rights to over three drug candidates, including PB272 (neratinib (oral)), PB272 (neratinib (intravenous)) and PB357. Neratinib is a potent irreversible tyrosine kinase inhibitor (TKI) that blocks signal transduction through the epidermal growth factor receptors (EGFRs), HER1, HER2 and HER4. Its initial focus is on the development of neratinib as an oral treatment of patients with HER2 positive metastatic breast cancer. It focuses on developing neratinib as an intravenously administered agent. The intravenous version of neratinib resulted in exposure levels of neratinib in pre-clinical models. Its product candidate, PB357, is an orally administered agent that is an irreversible TKI that blocks signal transduction through the epidermal growth factor receptors.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *